107 filings
10-Q
2024 Q2
CADL
Candel Therapeutics, Inc.
Quarterly report
13 Aug 24
8:30am
8-K
CADL
Candel Therapeutics, Inc.
13 Aug 24
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
8:15am
8-K
CADL
Candel Therapeutics, Inc.
28 Jun 24
Submission of Matters to a Vote of Security Holders
8:39am
ARS
2023 FY
CADL
Candel Therapeutics, Inc.
30 May 24
Annual report to shareholders
5:20pm
DEF 14A
CADL
Candel Therapeutics, Inc.
Definitive proxy
30 May 24
4:30pm
8-K
pr8t2c
30 May 24
Amendments to Articles of Incorporation or Bylaws
4:15pm
424B5
3u4 db9ah
24 May 24
Prospectus supplement for primary offering
7:30am
8-K
sa75ue551osp2
23 May 24
Regulation FD Disclosure
5:05pm
8-K
7ea4v1ikc wrl
14 May 24
Candel Therapeutics Reports First Quarter 2024 Financial Results
8:15am
8-K
1utqk6hs
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
8-K
pvwtf2ht18c akki5f
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
5h46vchgec4
9 Apr 24
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
8:30am
8-K
qq83uir0e bejfvx9
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
S-8
pvw1a2br
28 Mar 24
Registration of securities for employees
8:16am
8-K
p6ypi
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
8-K
siclukw77 mhp
6 Mar 24
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
8:00am
424B5
s999cuwc
13 Feb 24
Prospectus supplement for primary offering
9:00am